183 related articles for article (PubMed ID: 24344030)
1. CDC25B, Ki-67, and p53 expressions in reactive gliosis and astrocytomas.
Suren D; Isiksacan Ozen O
J BUON; 2013; 18(4):1006-11. PubMed ID: 24344030
[TBL] [Abstract][Full Text] [Related]
2. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
[TBL] [Abstract][Full Text] [Related]
3. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
[TBL] [Abstract][Full Text] [Related]
4. Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis.
Cummings TJ; Provenzale JM; Hunter SB; Friedman AH; Klintworth GK; Bigner SH; McLendon RE
Acta Neuropathol; 2000 May; 99(5):563-70. PubMed ID: 10805102
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade astrocytomas.
Kuriyama H; Lamborn KR; O'Fallon JR; Iturria N; Sebo T; Schaefer PL; Scheithauer BW; Buckner JC; Kuriyama N; Jenkins RB; Israel MA
Neuro Oncol; 2002 Jul; 4(3):179-86. PubMed ID: 12084348
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival.
Hiura T; Khalid H; Yamashita H; Tokunaga Y; Yasunaga A; Shibata S
Cancer; 1998 Dec; 83(11):2361-9. PubMed ID: 9840536
[TBL] [Abstract][Full Text] [Related]
7. Molecular markers relating to malignant progression in Grade II astrocytoma.
Yue WY; Yu SH; Zhao SG; Chen ZP
J Neurosurg; 2009 Apr; 110(4):709-14. PubMed ID: 19025355
[TBL] [Abstract][Full Text] [Related]
8. MIB-1 and p53 immunocytochemistry for differentiating pilocytic astrocytomas and astrocytomas from anaplastic astrocytomas and glioblastomas in children and young adults.
Matsumoto T; Fujii T; Yabe M; Oka K; Hoshi T; Sato K
Histopathology; 1998 Nov; 33(5):446-52. PubMed ID: 9839169
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of CDC25B expression in gliomas.
Nakabayashi H; Hara M; Shimizu K
J Clin Pathol; 2006 Jul; 59(7):725-8. PubMed ID: 16803948
[TBL] [Abstract][Full Text] [Related]
10. J1-31 protein expression in astrocytes and astrocytomas.
Shuangshoti S; Thorner PS; Ruangvejvorachai P; Saha B; Groshen S; Taylor CR; Malhotra S; Imam SA
Neuropathology; 2009 Oct; 29(5):521-7. PubMed ID: 19019178
[TBL] [Abstract][Full Text] [Related]
11. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
[TBL] [Abstract][Full Text] [Related]
12. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.
Rauscher J; Beschorner R; Gierke M; Bisdas S; Braun C; Ebner FH; Schittenhelm J
J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.
Tsidulko AY; Kazanskaya GM; Kostromskaya DV; Aidagulova SV; Kiselev RS; Volkov AM; Kobozev VV; Gaitan AS; Krivoshapkin AL; Grigorieva EV
Tumour Biol; 2017 Sep; 39(9):1010428317724282. PubMed ID: 28945172
[TBL] [Abstract][Full Text] [Related]
14. Role of gemistocytes in astrocytoma progression.
Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
[TBL] [Abstract][Full Text] [Related]
15. The role of immunohistochemistry in predicting behavior of astrocytic tumors.
Ambroise MM; Khosla C; Ghosh M; Mallikarjuna VS; Annapurneswari S
Asian Pac J Cancer Prev; 2010; 11(4):1079-84. PubMed ID: 21133628
[TBL] [Abstract][Full Text] [Related]
16. Detection of apoptotic cells in archival tissue from diffuse astrocytomas using a monoclonal antibody to single-stranded DNA.
Korkolopoulou PA; Konstantinidou AE; Patsouris ES; Christodoulou PN; Thomas-Tsagli EA; Davaris PS
J Pathol; 2001 Mar; 193(3):377-82. PubMed ID: 11241419
[TBL] [Abstract][Full Text] [Related]
17. Paraffin section p53 protein immunohistochemistry in neuroectodermal tumors.
Ng HK; Lo SY; Huang DP; Poon WS
Pathology; 1994 Jan; 26(1):1-5. PubMed ID: 8165016
[TBL] [Abstract][Full Text] [Related]
18. Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma.
Santosh V; Arivazhagan A; Sreekanthreddy P; Srinivasan H; Thota B; Srividya MR; Vrinda M; Sridevi S; Shailaja BC; Samuel C; Prasanna KV; Thennarasu K; Balasubramaniam A; Chandramouli BA; Hegde AS; Somasundaram K; Kondaiah P; Rao MR
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1399-408. PubMed ID: 20501753
[TBL] [Abstract][Full Text] [Related]
19. Factors predicting progression of low-grade diffusely infiltrating astrocytoma.
Ranjan M; Santosh V; Tandon A; Anandh B; Sampath S; Devi BI; Chandramouli BA
Neurol India; 2011; 59(2):248-53. PubMed ID: 21483127
[TBL] [Abstract][Full Text] [Related]
20. Expression of the p53 protein in a spectrum of astrocytic tumours.
Ellison DW; Gatter KC; Steart PV; Lane DP; Weller RO
J Pathol; 1992 Dec; 168(4):383-6. PubMed ID: 1336544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
